Literature DB >> 14657877

Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers.

Claudio D'ambrosio1, Cem Akin, Yalin Wu, Magnus K Magnusson, Dean D Metcalfe.   

Abstract

BACKGROUND: Mastocytosis is a rare clonal disorder that might be accompanied by non-mast-cell clonal hematologic disorders, such as myeloproliferative or myelodysplastic syndromes.
OBJECTIVE: Our aim was to further understand the pathologic basis of mastocytosis and to identify novel molecular markers of disease.
METHODS: Microarray analysis was performed on RNA preparations obtained from bone marrow mononuclear cells of patients with mastocytosis. Results were compared with gene expression profiles performed on bone marrow mononuclear cells of healthy subjects.
RESULTS: Analysis of gene expression in neoplastic bone marrow tissues revealed highly consistent profiles. One hundred four genes were significantly upregulated, and 64 genes were significantly downregulated in the bone marrow of patients with mastocytosis. The most prominent differentially expressed gene was alpha-tryptase (44.6-fold increase). Also upregulated were genes involved in cell proliferation, neoplastic transformation, and apoptosis. Both hierarchical and K-means clustering analyses identified an identical group of 10 genes highly coordinately overexpressed in patients with mastocytosis, including genes for the mast-cell-associated enzymes alpha- and beta-tryptase and carboxypeptidase A. The expression level of 3 of these 10 genes (alpha-tryptase, the activating transcription factor type 3, and the muscle aponeurotic fibrosarcoma type F oncogene) was significantly correlated with serum tryptase levels, a surrogate marker of disease.
CONCLUSION: The data presented in this study reveal significant differences in gene expression in the bone marrow of patients with mastocytosis compared with healthy subjects, demonstrate highly coordinated genes that might contribute to pathology, and identify 3 genes as candidate molecular markers for systemic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657877     DOI: 10.1016/j.jaci.2003.07.008

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

1.  Impaired function of bone marrow stromal cells in systemic mastocytosis.

Authors:  Krisztian Nemeth; Todd M Wilson; Jiaqiang J Ren; Marianna Sabatino; David M Stroncek; Miklos Krepuska; Yun Bai; Pamela G Robey; Dean D Metcalfe; Eva Mezey
Journal:  Stem Cell Res       Date:  2015-05-08       Impact factor: 2.020

Review 2.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

3.  The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis.

Authors:  B Haenisch; S Herms; G J Molderings
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  Long Noncoding RNA Maternally Expressed Gene 3 Is Downregulated, and Its Insufficiency Correlates With Poor-Risk Stratification, Worse Treatment Response, as Well as Unfavorable Survival Data in Patients With Acute Myeloid Leukemia.

Authors:  Chunling He; Xinmei Wang; Jing Luo; Yinghua Ma; Zhen Yang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 5.  Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.

Authors:  Boguslaw Nedoszytko; Michel Arock; Jonathan J Lyons; Guillaume Bachelot; Lawrence B Schwartz; Andreas Reiter; Mohamad Jawhar; Juliana Schwaab; Magdalena Lange; Georg Greiner; Gregor Hoermann; Marek Niedoszytko; Dean D Metcalfe; Peter Valent
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

6.  Expression of Carboxypeptidase A3 and Tryptase as Markers for Lymph Node Metastasis of Canine Cutaneous Mast Cell Tumors.

Authors:  Tuddow Thaiwong; Juliana V Cirillo; Jane Heller; Matti Kiupel
Journal:  Front Vet Sci       Date:  2022-02-14

7.  Mast cell activation syndrome as a significant comorbidity in sickle cell disease.

Authors:  Lawrence B Afrin
Journal:  Am J Med Sci       Date:  2014-12       Impact factor: 2.378

Review 8.  Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.

Authors:  Dean D Metcalfe; Ruby Pawankar; Steven J Ackerman; Cem Akin; Frederic Clayton; Franco H Falcone; Gerald J Gleich; Anne-Marie Irani; Mats W Johansson; Amy D Klion; Kristin M Leiferman; Francesca Levi-Schaffer; Gunnar Nilsson; Yoshimichi Okayama; Calman Prussin; John T Schroeder; Lawrence B Schwartz; Hans-Uwe Simon; Andrew F Walls; Massimo Triggiani
Journal:  World Allergy Organ J       Date:  2016-02-11       Impact factor: 4.084

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.